Lymphomas

Tazemetostat Approval Addresses Unmet Need in Relapsed/Refractory Follicular Lymphoma

June 26, 2020

In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.

Liso-cel Maintains Efficacy in Outpatient Setting for Patients With Large B-Cell Lymphomas

June 25, 2020

Liso-cel administration in the outpatient setting was implemented successfully in 3 clinical trials at academic and nonacademic medical centers.

FDA Lifts Partial Clinical Hold on Phase II Trial of Lacutamab in T-cell Lymphomas

June 24, 2020

The phase 2 TELLOMAK clinical trial is no longer on a partial clinical hold. As a result, trial enrollment with continue in patient with advanced T-cell lymphomas.

sNDA Seeks Expanded Approval of Ibrutinib in Waldenström's Macroglobulinemia

June 23, 2020

"The iNNOVATE study continues to deliver strong clinical evidence supporting the long-term use of ibrutinib plus rituximab across first and second lines of therapy for patients with Waldenström's macroglobulinemia."

Selinexor Introduces a New Mechanism of Action to Treat Relapsed or Refractory DLBCL

June 22, 2020

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Selinexor for R/R Diffuse Large B-Cell Lymphoma

June 22, 2020

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

Rolling NDA Submitted to FDA for Umbralisib as Treatment of Marginal Zone, Follicular Lymphomas

June 17, 2020

“The completion of this New Drug Application submission marks an important milestone in bringing us 1 step closer to providing umbralisib as a potential treatment option for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma."

Tafasitamab Plus Lenalidomide Demonstrates Long-Term Efficacy in R/R DLBCL

June 15, 2020

“These results, complimented with a favorable safety profile, indicate the utility of this novel immunological combination as a potential treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma."

Liso-Cel Leads to High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 13, 2020

"Treatment with liso-cel resulted in high response rates and durable complete responses in a patient population considered to be high risk.”

Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab Vedotin

June 10, 2020

John Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.